Skip to main content
Premium Trial:

Request an Annual Quote

Philips Incorporating Biodesix Nodify Test Into Lung Cancer Patient Management System

NEW YORK — Royal Philips said on Thursday that it is incorporating Biodesix's Nodify Lung lung nodule risk assessment test into its Philips Lung Cancer Orchestrator lung cancer patient management system.

Philips said it believes inclusion of results from Boulder, Colorado-based Biodesix's Nodify Lung test with radiological imaging and patient history data can help improve diagnosis and treatment of lung cancer.

Financial and other terms of the agreement were not disclosed.

Nodify Lung is a blood-based proteomic test that evaluates the likelihood that a lung nodule detected via low-dose computed tomography (LDCT) imaging is malignant. Most lung nodules detected by LDCT are benign and more than 60 percent of biopsies are done on nodules that turn out to be benign, making a noninvasive approach to determining the likelihood of malignancy potentially valuable.

Philips Lung Cancer Orchestrator is a system to help doctors manage patients both within LDCT lung cancer screening programs and who have presented with incidental lung nodule findings. The system tracks patients, appointments, diagnostic images, test results, and clinical decisions and aggregates data on tumor staging, radiology, pathology, and biomarker analyses to aid decision-making.

"By incorporating Biodesix's Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view," Louis Culot, general manager of oncology informatics and genomics at Philips, said in a statement.

"We are delighted that our tests are being incorporated into Philips' vision for end-to-end cancer care management using a multi-diagnostic approach," Biodesix CEO Scott Hutton said in a statement. "By integrating our Nodify tests in Philips Lung Cancer Orchestrator we hope to make these tests more accessible to physicians and patients and more easily utilized by care teams with the ultimate goal of improving patient care and outcomes."